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ABSTRACT
Objective To determine whether assessment tools for
non-randomised studies (NRS) address critical elements
that influence the validity of NRS findings for comparative
safety and effectiveness of medications.
Design Systematic review and Delphi survey.
Data sources We searched PubMed, Embase, Google,
bibliographies of reviews and websites of influential
organisations from inception to November 2019. In
parallel, we conducted a Delphi survey among the
International Society for Pharmacoepidemiology
Comparative Effectiveness Research Special Interest
Group to identify key methodological challenges for NRS
of medications. We created a framework consisting of
the reported methodological challenges to evaluate the
selected NRS tools.
Study selection Checklists or scales assessing NRS.
Data extraction Two reviewers extracted general
information and content data related to the prespecified
framework.
Results Of 44 tools reviewed, 48% (n=21) assess
multiple NRS designs, while other tools specifically
addressed case–control (n=12, 27%) or cohort studies
(n=11, 25%) only. Response rate to the Delphi survey
was 73% (35 out of 48 content experts), and a consensus
was reached in only two rounds. Most tools evaluated
methods for selecting study participants (n=43, 98%),
although only one addressed selection bias due to
depletion of susceptibles (2%). Many tools addressed the
measurement of exposure and outcome (n=40, 91%), and
measurement and control for confounders (n=40, 91%).
Most tools have at least one item/question on design-
specific sources of bias (n=40, 91%), but only a few
investigate reverse causation (n=8, 18%), detection bias
(n=4, 9%), time-related bias (n=3, 7%), lack of new-user
design (n=2, 5%) or active comparator design (n=0). Few
tools address the appropriateness of statistical analyses
(n=15, 34%), methods for assessing internal (n=15, 34%)
or external validity (n=11, 25%) and statistical uncertainty
in the findings (n=21, 48%). None of the reviewed
tools investigated all the methodological domains and
subdomains.
Conclusions The acknowledgement of major design-
specific sources of bias (eg, lack of new-user design,
lack of active comparator design, time-related bias,
depletion of susceptibles, reverse causation) and statistical

Strengths and limitations of this study
►► This is the first systematic review to investigate

whether existing tools adequately assess the validity
of non-randomised studies evaluating the comparative safety and effectiveness of medications.
►► Assessment tools were identified by searching
through multiple sources: relevant databases, grey
literature, websites of authoritative organisations,
bibliographies of previous systematic reviews and
experts’ suggestions.
►► The prepiloted framework adopted to evaluate the
completeness of the tools included all the main
methodological challenges suggested by an interdisciplinary (academia, industry and government
agencies) and international team of experts in the
field of pharmacoepidemiology and healthcare outcomes research.
►► Tools not published in English or that could not be
retrieved were omitted from this systematic review.
►► The search for tools in the grey literature might not
be comprehensive since it was performed through
only one browser.

assessment of internal and external validity is currently not
sufficiently addressed in most of the existing tools. These
critical elements should be integrated to systematically
investigate the validity of NRS on comparative safety and
effectiveness of medications.
Systematic review protocol and registration https://
osf.i o/es65q.

INTRODUCTION
There are high expectations that real-world
data (RWD) and resultant real-world evidence
(RWE) will become a key source of information for the development process of pharmacological or biological therapies.1–3 The 21st
Century Cures Act and the sixth Prescription
Drug User Fee Act required the Food and
Drug Administration (FDA) to explore the
use of RWE and, consequently, well-designed
and conducted non-
randomised studies
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METHODS
The systematic review was conducted according to the
Preferred Reporting Items for Systematic Reviews and
Meta-analyses statement.17 Systematic review protocol
and registration are available at https://osf.io/es65q.

manuals, tools to review study protocols, tools targeting
NRS of non-pharmacological interventions (eg, surgery)
or assessing only one or a few specific types of bias, and
tools not available in English language. In parallel, we
searched the same electronic databases for systematic
reviews of assessment tools of NRS. We then extracted
the references of the tools included in the systematic
reviews retrieved. We also performed a general search
through Google for grey literature and reviewed any
additional information from initiatives, programmes
or organisations. Full details on the search strategy are
reported in the supplement (online supplemental tables
S1 and S2). Three reviewers (ED, GS and LV) independently removed duplicates and reviewed titles and
reviewed publications or documents
abstracts of peer-
from the grey literature to select eligible tools. Discrepancies were resolved by consensus.
Delphi survey and prespecified framework
Concurrently, we performed a Delphi survey18 to reach a
consensus among content experts about the main methodological challenges (domains) that may threaten the
validity of NRS on comparative safety and effectiveness
of medications. The survey is available in the online
supplemental 2. The panel of experts involved members
of the SIG for CER of the ISPE. Detailed information on
the Delphi methods and results is reported in the online
supplemental 1.
Domains and subdomains indicated by the Delphi
respondents as major elements that can impact the
validity of NRS of medications were used to develop and
pilot a framework to evaluate the identified NRS tools. All
domains were considered equally important. A glossary of
terms used in the framework is reported in table 1.
Data extraction
Two reviewers (ED and LV) independently extracted general
information of the identified tools (first author or name of
the tool, year of publication or online availability of the most
updated version, type of tool, scope of the tool, NRS designs
evaluated and number of items) and content data related
to the prespecified domains of the framework. Discrepancies were resolved by consensus. We categorised the tools as
checklists, defined as itemised instruments (including questionnaires) developed to identify the presence or absence of
critical elements, or rating scales, defined as itemised instruments aimed to identify the performance of a study at each
critical element described in the tool, using a qualitative or
quantitative scale.

Systematic search and eligibility criteria
We searched PubMed and Embase from inception to
November 2019 to identify existing tools that investigated the validity of NRS, specifically case–control
and cohort design studies. We excluded guidelines or

Data synthesis
General characteristics of the identified tools were
summarised with means and SD, for continuous variables, and relative frequencies, for categorical variables.
The findings from the Delphi survey and the proportion
of tools assessing the prespecified elements of the framework were reported in terms of relative frequencies.
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(NRS) for expediting drug approvals.4 5 Similarly, one
of the goals of the European Medicines Agency (EMA)
Adaptive Pathways Initiative is to supplement clinical trial
data with RWD and to eventually produce RWE as part of
the approval process of new medications or indications.6
However, the growing demand for RWD has raised
concerns about the reliability of NRS to generate RWE.
Due to the inherent limitations of observational analyses,
the validity of NRS depends largely on the implementation of complex design and analytic methodologies.
In recent reports, both FDA and EMA emphasised the
need to plan and execute NRS following standards that
can ensure validity and reproducibility of RWE.7 8 Tools
that assess the validity of NRS can be useful instruments
for both researchers (eg, for authors and reviewers to
prevent publication of poor quality pharmacoepidemiological research) and other stakeholders who are involved
in clinical, managemental or economic decision making
(eg, to correctly inform guidelines and clinicians or to
guide resource allocation).
An analysis on the capability of existing tools to assess
the validity of NRS of comparative safety and effectiveness
of medications is currently lacking. Previously published
systematic reviews on assessment tools for NRS were
mostly descriptive and did not provide a critical evaluation of the tools content,9–13 investigated only a specific
type of bias14 or focused only on safety outcomes.15
Therefore, we conducted a systematic review to assess the
content of eligible tools for NRS of medications. There
is no agreement on an assessment framework for NRS of
pharmacological interventions. Thus, we performed a
Delphi survey among international experts in the field of
pharmacoepidemiology and health outcome research in order to
build consensus for the methodological challenges that
may threaten the validity of NRS of medications and that
should be evaluated by assessment NRS tools.
The main objective of this study was to determine
whether the retrieved NRS tools sufficiently address the
main methodological challenges recommended by the
experts. This study is part of a research project to develop
a framework for the synthesis of NRS and randomised
controlled trials (RCTs),16 led by the Comparative Effectiveness Research Special Interest Group (CER SIG) of
the International Society for Pharmacoepidemiology
(ISPE).

Open access

Term

Definition

Active comparator design A study design that compares the effect of the drug of interest with another drug used in clinical
practice instead of non-use.
Adjustment for causal
Adjustment for an intermediate variable (or a descending proxy for an intermediate variable) on a
intermediaries
causal path from exposure to outcome.
Case–control design

A study design in which cases (patients with outcomes) are identified and compared with controls
(patients without outcomes) with respect to the exposure of interest.

Cohort design

A study design in which a group of patients (a cohort) is identified and followed to ascertain the
occurrence of an outcome.

Confounding

A mixing of effects that arises when patients with different baseline risks are compared; the
resulting effect measure is a mix of drug effects and risk factor effects.

Depletion of susceptibles Selection bias that occurs when the initiation of exposure to a drug is associated with an early
increased incidence rate of the study outcome, followed by a decreased incidence rate with longer
duration of exposure (eg, users of new drugs are compared with users of older drugs).
Detection or surveillance
bias

Bias that occurs when the degree of outcome surveillance (or an associated symptom) is related to
exposure and is differential among the exposure groups.

Immortal time bias

Time-related bias that derives from including a period of follow-up during which, by design,
outcomes cannot occur.

Time-window bias

Time-related bias, in the context of a case–control study nested in a cohort, that derives from the
use of time-windows of different lengths between cases and controls to define time-dependent
exposures.

Incorrect outcome model Misspecification of a statistical model that leads to biased outcome results. Common causes are
specification
omission of a relevant variable, inclusion of an unnecessary variable, adopting the wrong functional
form, incorrect specification of the error term, uncertainty about what the true model is and
reciprocal causation.
Loss to follow-up bias

Bias that occurs when there is difference in retention during the follow-up period after enrolment
that are related to exposure status and outcome.

New-user design

A study design that starts following patients at the time they initiate a new drug (also known as
incident-user design)

Non-contemporaneous
comparator bias

Bias generated by differences in the timing of selection of comparator group(s) within a study
influence exposures and outcomes resulting in biased estimates.

Reverse causation (or
reverse causality)

Bias due to direction of cause and effect contrary to a common presumption, or a two-way causal
relationship between exposure and outcome.

Recall bias

Bias that occurs when participants do not remember previous events or experiences accurately or
omit details (not for claims-based studies).
Bias that occurs when selection of participants or follow-up time is related to both intervention
and outcome (eg, prevalent users of a drug are compared with non-users or incident users). Our
framework has a separate subdomain that refers to selection bias due to lack of generalisability,
applicability or transferability to patients who were excluded from the study.

Selection bias

RESULTS
Overview of tools
Of 44 tools that met our eligibility criteria,19–52 20 (45%)
were identified through the database search of peer-
reviewed literature and 24 (55%) through the general
online search and other sources (online supplemental
figure S1 and table S3). Characteristics of the tools are
shown in tables 2 and 3. The number of items across all
tools ranged from 5 to 54, with a median of 13.5 (IQR
10.3–22). Only three tools were designed to specifically
address studies on the comparative safety and effectiveness of pharmacological interventions: one published
in 1994 by Cho and Bero,46 the The Good ReseArch
for Comparative Effectiveness (GRACE) checklist and
D'Andrea E, et al. BMJ Open 2021;11:e043961. doi:10.1136/bmjopen-2020-043961

the International Society for Pharmacoeconomics
and Outcomes Research – Academy of Managed Care
Pharmacy – National Pharmaceutical Council (ISPOR-
AMCP-NPC) tool, both published in 2014.25 26
Tool formats and scopes
Most of the tools were checklists (n=35, 80%), and 13
checklists included a final section to elaborate a summary
judgement of the study appraisal (37%). The remaining
tools were scales (n=9, 20%), and six of them provided a
section for a summary judgement (67%).
Thirty-five tools (80%) were designed as critical appraisal
tools for different scopes (eg, assessing the quality of NRS
included in a systematic review, screening eligible NRS to
3

BMJ Open: first published as 10.1136/bmjopen-2020-043961 on 24 March 2021. Downloaded from http://bmjopen.bmj.com/ on March 26, 2021 by guest. Protected by copyright.

Table 1 Glossary of terms

Open access

Scope of the tool

Study design
evaluated

tems

Checklist

Critical appraisal and reporting

NRS

21

Rating scale+summary judgement

Critical appraisal

Coh (+RCTs), CC Coh (+RCTs) 21, CC 18

Tool identified*

Year

Type of tool

RELEVANT

2019

RAMboMAN - GATE-EPIQ

2019

MMAT

2018

Checklist

Critical appraisal

NRS

CASP

2018

Checklist

Critical appraisal

Coh, CC

Coh 12, CC 11

5

SURE

2018

Checklist+summary judgement

Critical appraisal

Coh, CC

Coh 13, CC 11

JBI

2017

Checklist+summary judgement

Critical appraisal

Coh, CC

Coh 11, CC 10

ROBINS-I

2016

Checklist+summary judgement

Critical appraisal

NRS

34 (+8 optional
question)

ISPOR-AMCP-NPC†

2014

Checklist+summary judgement

Critical appraisal

Coh CC

32

GRACE†

2014

Checklist+summary judgement

Critical appraisal

Coh CC

11

NIH–NHLBI

2014

Checklist+summary judgement

Critical appraisal

Coh (+CSS), CC

Coh (+CSS) 14, CC 12

HEBW

2014

Checklist+summary judgement

Critical appraisal

Coh

18

RoBANS

2013

Rating scale

Critical appraisal

NRS

6

RTI-Item Bank

2013

Checklist

Critical appraisal

NRS

13

Newcastle-Ottawa

2013

Rating scale +summary judgement

Critical appraisal

Coh, CC

Coh 8, CC 8

SIGN - V.3.0

2012

Checklist+summary judgement

Critical appraisal

Coh, CC

Coh 14, CC 11

Montreal

2011

Checklist

Critical appraisal

Coh CC (+RCTs) 10

EPHPP

2011

Rating scale

Critical appraisal

Coh CC (+RCTs) 17

STROBE – V.4

2007

Checklist

Reporting

Coh, CC

Coh 22, CC 22

TREND

2004

Checklist

Reporting

NRS

22

Margetts

2002

Checklist

Reporting

Coh CC

11

Zaza

2000

Checklist

Critical appraisal

Coh CC

15

Downs-Black

1998

Rating scale

Critical appraisal and reporting

Coh CC (+RCTs) 27

Elwood

1998

Checklist

Critical appraisal

Coh CC (+RCTs) 20

Hadorn

1996

Checklist

Critical appraisal

Coh (+RCTs)

London

1996

Checklist

Critical appraisal

Coh CC

Avis

1994

Rating scale+summary judgement

Critical appraisal and reporting

Coh CC (+RCTs) 24

Durant

1994

Checklist

Critical appraisal

CC

Levine

1994

Checklist

Critical appraisal

Coh CC (+RCTs) 10

Gyorkos

1994

Checklist

Critical appraisal

Coh, CC

Coh 6, CC 5

Cho†

1994

Rating scale+summary judgement

Critical appraisal

NRS (+RCTs)

24

COEH

1991

Checklist

Critical appraisal

NRS

54

Fowkes-Fulton

1991

Checklist+summary judgement

Critical appraisal and reporting

NRS (+RCTs)

Lichtenstein

1987

Checklist

Critical appraisal

CC

7
33
23

6
20

Gardner

1986

Checklist

Critical appraisal

NRS

12

Horwitz

1979

Checklist

Critical appraisal and reporting

CC

12

Nine tools from our bibliographic search provided two separate instruments to assess cohort or case–control studies. Thus, the overall number of included records
is 35, while the number of included assessment tools is 44.
*Tool name or first author name, if the tool does not have an assigned name, and it was published in peer-review journals.
†Tool developed to assess NRS on the comparative safety and effectiveness of medications.
CASP, The Critical Appraisals Skills Programme; CC, case–control study; COEH, Centre for Occupational and Environmental Health of The University of Manchester;
Coh, cohort study; CSS, cross-sectional study; EPHPP, Effective Public Health Practice Project Quality Assessment Tool; GRACE, The Good ReseArch for
Comparative Effectiveness; HEBW, Health Evidence Bulletins Wales; ISPOR-AMCP-NPC, International Society for Pharmacoeconomics and Outcomes Research
– Academy of Managed Care Pharmacy – National Pharmaceutical Council; JBI, The Joanna Briggs Institute; MMAT, Mixed Methods Appraisal Tool; NIH–NHLBI,
The National Institute of Health - The National Heart, Lung, and Blood Institute; NRS, non-randomised studies; RAMboMAN, GATE-EPIQ, Recruitment Allocation
Maintenance blind objective Measurements Analyses, Graphic Approach To Epidemiology – Effective Practice, Informatics and Quality Improvement; RCTs,
randomised controlled trials; RELEVANT, The REal Life EVidence AssessmeNt Tool; RoBANS, Risk of Bias Assessment tool for Non-randomized Studies; ROBINS-I,
Risk Of Bias In Non-randomized Studies of Interventions; RTI-Item Bank, Research Triangle Institute Item Bank; SIGN, The Scottish Intercollegiate Guidelines
Network; STROBE, STrengthening the Reporting of OBservational studies in Epidemiology; SURE, Specialist Unit for Review Evidence; TREND, Transparent
Reporting of Evaluations with Non-randomized designs.

include in systematic reviews to support clinical guidelines,
supporting peer-review processes or, more general, allowing
readers to interpret NRS results critically). Four tools (9%)

were developed to assess the quality of reporting and were
mainly intended for researchers. Five other tools (11%)
combined elements of both critical appraisal and quality

4
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Table 2 Individual characteristics of the tools included in the systematic review
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Characteristics
Publication year, n (%)
 1979–1989

All,
n=44

Cohort*,
n=11

Case–control,
n=12

NRS†,
n=21

3 (7)

0 (0)

2 (17)

1 (5)

12 (27)

2 (18)

2 (17)

8 (38)

 2000–2009

5 (11)

1 (9)

1 (8)

3 (14)

 2010–2019

24 (55)

8 (73)

7 (58)

9 (43)

 Checklist

22 (50)

4 (36)

6 (50)

12 (57)

 Checklist+summary judgement

13 (30)

5 (45)

4 (33)

4 (19)

 Rating scale

3 (7)

0 (0)

0 (0)

3 (14)

 Rating scale+summary judgement

6 (14)

2 (18)

2 (16)

2 (9)

 1990–1999

Type of tool, n (%)

Scope of the tool, n (%)
 Critical appraisal

35 (80)

9 (81)

10 (83)

16 (76)

 Reporting

4 (9)

2 (18)

1 (8)

1 (5)

 Critical appraisal and reporting

5 (11)

0 (0)

1 (8)

4 (19)

Tools designed for CER, n (%)
Number of items, median (IQR)

3 (7)
13 (10.3–21.8)

0 (0)
13 (9.5–16)

0 (0)
11.5 (10.8–18.5)

3 (14)
17 (11–24)

*Two tools evaluated both cohort and RCTs together; one tool evaluated both cohort and cross-sectional studies together.
†NRS tools refer to a single tool built to evaluate both cohort and case–control studies or a tool built to evaluate additional NRS (eg, cross-
sectional studies and before–after studies) together with cohort and case–control studies. Eight NRS tools included also the evaluation of
RCTs.
CER, Comparative Effectiveness research; NRS, non-randomised studies; RCTs, randomised controlled trials.

reporting and were for a more general audience (both
researchers and readers) (tables 2 and 3).
Study designs addressed
Twenty-one tools (48%) were developed to assess multiple
NRS designs (11 targeted cohort and case–control studies
and 10 others addressed also other NRS designs or did not
specify them). Other tools specifically addressed case–control
(n=12, 27%) or cohort studies (n=11, 25%). Ten tools (23%)
were designed to assess also RCTs.

Measurement of exposure, outcomes, covariates and follow-up
Forty-two tools (95%) had at least one item assessing the
definition and measurement of exposure, outcome, covariates and follow-up. Assessment of exposure and outcome was
widely reported by the tools (n=40, 91%), while definition
and measurement of covariates (n=12, 27%) or follow-up
(n=17, 39%) were less often addressed (with the exception
for tools addressing follow-up in cohort studies only, n=9,
82%) (table 4 and online supplemental figure S4).

Methods for selecting participants
Nearly all tools assessed methods for selecting study participants to correct selection bias (n=43, 98%). Specifically,
almost half of the tools included items related to sampling
strategies (n=19, 43%), the definition of inclusion and exclusion criteria (n=27, 61%) and the generalisability of participants (ie, attempts to achieve a sample of participants that
represents the target population) (n=21, 48%), while only
one tool addressed the depletion of susceptibles (n=1, 2%)
(table 4 and online supplemental figure S3).

Design-specific sources of bias
Design-specific sources of bias (excluding selection bias which
was investigated in ‘Methods for selecting participants’) were
assessed by 91% of the tools (n=40) and generally included
loss to follow-up bias (n=22, 50%), observer or interviewer
bias (n=11, 25%), reverse causation bias (n=8, 18%), recall
bias (n=6, 14%) and non-contemporaneous comparator bias
(n=6, 14%). A few or no tools assessed detection or surveillance bias (n=4, 9%), time-related bias, such as immortal
person-time bias or time-window bias (n=3, 7%), and biases
due to lack of new-user design (n=2, 5%) or active comparator design (n=0). Other tools reported only a general item/
question on the risk of bias (n=9, 20%), without any reference to a specific type of bias.
Tools specifically for cohort studies addressed more
frequently loss to follow-up (n=9, 82%) and reverse causation
biases (n=5, 45%) compared with the other tools, while
tools for case–control studies addressed mostly recall (n=4,

D'Andrea E, et al. BMJ Open 2021;11:e043961. doi:10.1136/bmjopen-2020-043961
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Tool elements
The response rate of the Delphi survey was 73% (35 respondents out of 48 members). Detailed results are reported in
the online supplemental figure S2. Domains and subdomains indicated by the respondents as major elements that
can impact the validity of NRS of medications are reported in
the first column of table 4.
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Table 3 General characteristics of the assessment tools included in the systematic review
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Domains

Cohort tools*,
n=11

Case–control
tools, n=12

NRS tools†,
n=21

Total,
n=44

1. Methods for selecting participants, n (%)

11 (100)

12 (100)

20 (95)

43 (98)

 Sampling strategies to correct selection bias

4 (36)

6 (50)

9 (42)

19 (43)

 Inclusion and exclusion criteria of target population

6 (55)

8 (67)

13 (61)

27 (61)

 Depletion of susceptibles

1 (9)

0 (0)

0 (0)

1 (2)

 External validity of target population

6 (55)

6 (50)

9 (43)

21 (48)

 Others‡

11 (100)

12 (100)

18 (86)

41 (93)

2. Measurement of exposure, outcomes, covariates and follow-up, n (%)§

11 (100)

12 (100)

19 (90)

42 (95)

 Measurement of exposure§

11 (100)

11 (92)

18 (81)

40 (91)

 Measurement of outcomes§

11 (100)

11 (92)

18 (81)

40 (91)

 Measurement of covariates

4 (36)

4 (33)

4 (19)

12 (27)

 Measurement of follow-up

9 (82)

3 (25)

5 (24)

17 (39)

11 (100)

10 (83)

19 (90)

40 (91)

0 (0)

0 (0)

3. Design-specific sources of bias, n (%)
 New-user design

2 (10)

2 (5)

 Active comparator design

0 (0)

0 (0)

0 (0)

0 (0)

 Immortal time bias or time-window bias

0 (0)

0 (0)

3 (14)

3 (7)

 Detection or surveillance bias

1 (9)

2 (17)

1 (5)

4 (9)

 Loss to follow-up bias

9 (82)

1 (8)

12 (57)

22 (50)

 Non-contemporaneous comparator bias

0 (0)

1 (8)

5 (24)

6 (14)

 Reverse causation

5 (45)

1 (8)

2 (10)

8 (18)

 Recall bias¶

1 (9)

4 (33)

1 (5)

6 (14)

 Interviewer or observer bias¶

1 (9)

3 (25)

7 (35)

11 (25)

 Ascertainment bias¶

0 (0)

1 (8)

1 (5)

2 (5)

 General item/question on bias¶

3 (27)

3 (25)

3 (14)

9 (20)

 Other biases**

0 (0)

2 (17)

5 (24)

7 (16)

11 (92)

18 (86)

40 (91)

4. Confounding, n (%)

11 (100)

 Study design used to minimise confounding

6 (55)

7 (58)

13 (62)

26 (59)

10 (91)

10 (83)

18 (86)

38 (86)

 Potential unmeasured confounding addressed in the analysis (eg, proxy
analysis and IV analysis)

1 (9)

1 (8)

3 (14)

5 (11)

5. Lack of appropriateness of statistical analyses (with specific mention of
overadjustment and/or incorrect outcome model specification), n (%)

2 (18)

3 (25)

10 (48)

15 (34)

6. Methods for assessing statistical uncertainty in the findings (eg, CIs
reported for each analysis), n (%)

7 (64)

6 (50)

8 (38)

21 (48)

7. Methods for assessing internal validity (eg, sensitivity analysis addressing
potential confounding, measurement errors or other biases), n (%)

3 (27)

3 (25)

9 (43)

15 (34)

8. Methods for assessing external validity (eg, post hoc subgroup analysis
and comparison with other populations), n (%)

4 (36)

3 (25)

4 (19)

11 (25)

 Confounders measured and included in statistical analyses

*Two tools evaluated both cohort and RCTs together; one tool evaluated both cohort and cross-sectional studies together.
†NRS tools refer to a single tool built to evaluate both cohort and case–control studies or a tool built to evaluate additional NRS (eg, cross-sectional
studies and before–after studies) together with cohort and case–control studies. Eight NRS tools included also the evaluation of RCTs.
‡'Others’ refers to items not included in our evaluation framework but included in the reviewed tools to investigate selection bias (eg, population
characteristics sufficiently described to determine the applicability of the research question, sample size justification and power description, and
ethical considerations).
§Items or questions on exposure misclassification and/or outcome misclassification are counted in this domain and relative subdomains.
¶Design-specific biases not included in the evaluation framework but addressed by the reviewed tools.
**Other design-specific biases not included in the evaluation framework but addressed by a few tools (eg, bias due to missing data, patients'
blinding, different length of follow-up between groups, Berkson’s bias and protopathic bias).
IV, instrumental variable; NRS, non-randomised studies; RCTs, randomised controlled trials.

33%) and observer biases (n=3, 25%). Tools for multiple
NRS covered commonly loss to follow-up (n=12, 57%) and
interviewer or observer biases (n=7, 35%) (table 4 and online
supplemental figure S5).

Confounding
Forty tools (91%) included at least one item or question
related to confounding. Specifically, 26 tools (59%) searched
whether study design was planned in a way to minimise
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Table 4 Methodological challenges addressed by the included assessment tools

Open access

Appropriateness of statistical analyses, external and internal
validity
One-third of the tools (n=14, 32%) assessed the appropriateness of statistical analyses, although most of them did not
explicitly mention overadjustment of causal intermediates
and/or incorrect outcome model specification. Almost half
(n=21, 48%) included methods for measuring uncertainty
in the findings. Few tools addressed methods for evaluating internal (n=15, 34%) or external validity (n=11, 25%)
(table 4 and online supplemental figure S7 in the online
supplement).
These results were mostly consistent across the three
different types of design addressed, cohort only, case–
control only and multiple NRS, except for the assessment of follow-up (domain 2) and several design-specific
sources of biases (domain 3) already mentioned above
(table 4). None of the reviewed tools covered all the main
domains and subdomains as identified by the CER SIG
and listed in table 4.
Results for each selected tool on the proportions of
items/questions that investigate the prespecified domains
are shown in the online supplemental figures S8–S11.

DISCUSSION
In this systematic review, we identified assessment tools
evaluating the validity of NRS on comparative safety and
effectiveness of medications. Of 44 tools included, only
three were specifically designed to assess NRS of pharmacological interventions.25 26 46
Main findings
Overall, we found that existing tools assessed most of the
methodological challenges identified by the domains of
the CER SIG framework, but critical elements were often
insufficiently addressed. For example, although many
tools assessed the risk of selection bias, only half of them
explicitly investigated sampling strategies and considered a prespecification of inclusion/exclusion criteria.
Even more surprising was that only one tool explored the
potential for selection bias due to depletion of patients
that are susceptible to the outcome. This cohort-based
phenomenon can occur when new users of a medication
are depleted of all susceptible subjects to the outcome,
documenting an increased incidence rate of the outcome
in an early stage, followed by a decreased rate with a
longer duration of exposure.53 Depletion of susceptibles
is an important source of bias to account for when evaluating effects of new medications in incident users and can
significantly undermine the validity of the results.53
Similarly, many tools investigated misclassification or
information bias of exposure and outcome. However, only
about one-third assessed definition and measurement of
D'Andrea E, et al. BMJ Open 2021;11:e043961. doi:10.1136/bmjopen-2020-043961

covariates, and less than one-fourth of the case–control
and multiple NRS designs tools assessed information on
follow-up definition. Again, these are common causes of
bias and should be integrated in tools that investigate the
validity of NRS.
Design-specific sources of bias was a critical domain.
Although overall 91% of the tools had at least one item/
question investigating biases due to an inappropriate
study design, only Risk Of Bias In Non-
randomized
Studies of Interventions (ROBINS-
I) and the GRACE
checklist addressed bias due to lack of new-user design
and time-related bias (ie, immortal person-time bias or
time-window bias), while no tools investigated bias due
to lack of active comparator design. Since these biases
can independently lead to major methodological flaws
(defined as elements that by themselves can significantly
compromise the validity of the results), their assessment
must be included in appraisal tools for NRS of pharmacological interventions. For example, recent evidence on
NRS of glucose-lowering medications reported that only
one-fourth of the studies adopted a new-user design and
less than half used an active comparator.54 In the same
example, potential for time-
related bias was detected
in more than two-
third of the studies.54 Integrating
the evaluation of these major methodological flaws in
existing tools and recommending the use of these tools
before publication can increase awareness in the clinical
research community with respect to main design-specific
biases. This can ultimately decrease the amount of NRS
with invalid findings on the safety or effectiveness of
medications.
A high percentage of tools evaluated whether
confounders were appropriately measured, controlled
for in the analysis and considered in the study design.
However, very few tools included at least one item/question on whether potential unmeasured confounding
had been considered in the analysis or interpretation of
findings.
One-third of the tools checked the appropriateness of
statistical analyses, but most omitted specific reference
to common flaws such as overadjustment or incorrect
outcome model specification. Similarly, only one-third of
the tools assessed internal validity (eg, through sensitivity
analysis to address potential confounding, measurement
errors or other biases), and only one-
fourth assessed
external validity (eg, post hoc subgroup analysis and
comparison with other populations).
Implications for practice and research
While recently published tools such as The Critical Appraisals Skills Programme checklist,21 ISPOR-
AMCP-NPC,25 Recruitment Allocation Maintenance
blind objective Measurements Analyses,19 GRACE26
and ROBINS-I24 are among the most complete tools,
addressing several of the critical elements underlined by
the ISPE CER SIG, they all had limitations in the acknowledgement of two or more major methodological challenges (eg, selection bias for depletion of susceptibles,
7
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confounding, 38 (86%) whether confounders were measured
and included in the analyses and only five whether potential
unmeasured confounding was assessed in the sensitivity analyses (11%) (table 4 and online supplemental figure S6).

Open access
the comparative safety and effectiveness of medications.
Previously published systematic reviews on assessment
tools for NRS were not specifically focused on pharmacological interventions,9 10 included randomised study
designs11–13 or investigated only a specific type of bias.14
One systematic review of NRS tools for medications
focused only on safety outcomes, and it is now outdated
since published in 2012.15 Our systematic review has
multiple strengths: authors reviewed the results of the
searches independently following a predefined protocol;
the framework for data extraction was developed based
on inputs of worldwide experts in the field of pharmacoepidemiology and healthcare outcomes research
coming from different backgrounds (academia, industry
and governmental agency) and different countries, and
it included the most updated versions of the identified
tools. This review also has limitations. Search for tools in
the grey literature might not be comprehensive since it
was performed through only one browser. The search was
also restricted to tools published in English and excluded
identified tools that could not be retrieved.

CONCLUSION
In this systematic review, we found that available tools for
NRS assessment failed to provide a comprehensive assessment of major methodological aspects that can affect the
validity of NRS on the comparative safety and effectiveness of medications. Specifically, major aspects such as
lack of new-user design, active comparator design, time-
related bias (ie, immortal time bias and time-
window
bias) and statistical assessment of internal validity remain
poorly covered. Including these critical elements into
existing tools may provide a more accurate instrument
to evaluate NRS of pharmacological interventions and
increase awareness in the clinical research community
about major addressable flaws in pharmacoepidemiology.
This may improve the validity of NRS on the comparative
safety and effectiveness of medications and reduce the
publication of studies with unreliable findings.

Strengths and limitations
To our knowledge, this is the first systematic review that
investigated whether existing tools adequately assess the
validity of cohort and case–control studies evaluating
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immortal-
time bias or window-
time bias, lack of new-
user design, lack of active comparator design, reverse
causation bias and adjustment for causal intermediaries). Assessment tools can be powerful instruments for
researchers, authors, reviewers of scientific journals or
readers, helping to identify the main limitations of a study
and to correctly interpret the results, to acknowledge
major methodological flaws and, ultimately, to prevent
publication of studies with invalid findings.
Furthermore, other decision makers, such as clinicians,
guideline developers and payers or investors, can benefit
from instruments that help to ensure the validity of NRS
findings. RCTs can be an insufficient source of evidence
for decisions on pharmaceutical interventions.55 56 Despite
well-designed and adequately powered RCTs being considered the ‘gold standard’ of the clinical research paradigm,
they can often be too time intensive and money intensive. Trials are often relatively small, focus on short-term
efficacy and safety in a controlled clinical environment,
using surrogate outcomes or under-representing high-risk
populations that can be most likely the target on the new
medications in the real-world setting.55 56 Trials might also
not record treatments taken outside the study protocol.47
Additionally, patients volunteered to participate in a
trial are usually very motivated and so more adherent
to therapy compared with the real-world population.56
NRS based on RWD can help to address these issues and
could be supplement the evidence from RCTs to provide
a more complete picture on the effectiveness of pharmaceutical interventions in less controlled environments.
NRSs have the advantages to investigate large-scale populations, high-risk subpopulations, rare exposures, diseases
or outcome, and long-term outcomes or other delayed
health effects at low costs and rapidly.55 56 Moreover, since
RWD are often collected for intents unrelated to research
objectives (mainly administrative), biases such as recall
bias, interviewer bias, non-response bias and bias for loss
to follow-
up are reduced or eliminated.55 Thus, since
RWE derived by NRS contribute significantly to generate
evidence of comparative effectiveness research of medications, our synthesis can help numerous stakeholders to
evaluate whether the NRS considered are valid enough to
guide decision making.
Although checklists have been previously suggested
for reviewing the risk of bias of general NRS,57 we cannot
strongly recommend a specific tool for NRS on comparative analyses of medications. As already mentioned, items
or questions that address all those methodological flaws
must be integrated in the existing tools. Based on our
findings, most recent and comprehensive tools such as
ROBINS-I24 and GRACE26 assessed a higher number of
major methodological elements and could therefore be
prioritised in this endeavour.
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In this supplement, we describe in greater detail the methods and results of our review process and
Delphi survey and report additional findings related to the evaluation of each assessment tool.
As stated in the main manuscript, the framework to evaluate the assessment tools was developed
based on the domains and subdomains indicated by the Comparative Effectiveness Research (CER)
Special Interest Group (SIG) as the main critical elements that can threat to the validity of nonrandomized studies (NRS) of medications.

Delphi Survey
To collect the domains and to ultimately develop the evaluation framework, we performed a
survey following the Delphi methodology. This is an iterative multistage process that uses rounds of
questionnaires to reach a consensus among content experts [Hasson et al. 2000]. The survey targeted all
members of the SIG of the International Society for Pharmacoepidemiology CER. These experts were
informed about the survey during an online meeting hold on July 1, 2019. During the meeting, study
protocol and Delphi survey were presented to the group, addressing that answering to the survey would
have constituted consent to participate in the study. After the online meeting, the study protocol was emailed to the members of CER SIG.
On August 23, 2019, a link to a self-administered online questionnaire was sent by email to 48
CER SIG members. In the first page of the survey, a cover letter outlined the purpose of the study and
assured the participants of anonymity in processing the results. The online questionnaire could have only
been submitted once per person. The experts had three weeks to answer after the initial e-mail, during this
time one remainder was sent.
The two-section questionnaire was developed through several face-to-face and online meetings
among the authors. The first section included questions on demographic and professional information of
participants. In the second section, respondents were asked to rate, on a five-point scale ranging from 1
(“not important”) to 5 (“extremely important”), which items should be considered when assessing the
overall quality of a NRS, specifically cohort and case-control studies, of pharmacological interventions.
2

D'Andrea E, et al. BMJ Open 2021; 11:e043961. doi: 10.1136/bmjopen-2020-043961

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

BMJ Open

In addition to the rating, the respondents had the option of providing any other relevant considerations at
the end of the questionnaire (see Supplement 2).
The outcome variable of the online survey, originally consisting of five categories, was collapsed
into two levels. Participants considered important an item if they rated it 4 or 5 (where 5 is “extremely
important”), while they did not consider an item of key importance if they rated it 1, 2 or 3 (where 1 is
“not important”). When at least 70% of participants agreed on the importance of an item (rating 1, 2 or 3
vs rating 4 or 5), we considered that a consensus had been reached on that item.
Thirty-five CER SIG experts participated to the first round of the survey (response rate = 73%).
Eighteen respondents worked in academia (51%), 16 respondents worked in industry (46%), and only one
was affiliated to a governmental institution (3%). The majority of respondents were from U.S. (n = 26,
74%), the others were from Europe (n = 7, 20%) or from Canada (n = 2, 6%). After participants ranked
the relevance of the items and provided comments to the first questionnaire, we reviewed the responses
and adjusted the survey to reflect the feedback. Overall, participants considered the presented domains
important or extremely important. All domains, other than the domain n. 5 (“Lack of appropriateness of
statistical analyses”), were rated relevant with unanimous consent (100% of participants rated them 4 or
5). For the domain n. 5 (“Lack of appropriateness of statistical analyses (with specific mention of
adjustment for causal intermediaries, and/or incorrect outcome model specification)” in the Supplement
2), only three participants did not consider it important. Based on individual experts’ suggestions, we
added the subdomain “External validity of target population” to domain n. 1 “Methods of selecting
participants” to address the external validity or generalizability of the study population to the eligible or
target population. We removed “Recall bias” from the critical elements of domain n. 3 since this was the
only domain to be rated not relevant by most of participants (n = 26, 74%). The rationale provided was
that, since real world data (RWD) are often collected for intents unrelated to pursue research goals (e.g.,
administrative purposes), biases such as recall bias, interviewer bias, nonresponse bias are usually
reduced or even eliminated [Sørensen HT et al.].
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A revised survey was returned to the same participants for reassessment of the content. The
response rate to the second round was 89% (n = 31/35). Since in this second round the threshold of 70%
was reached for all the old and new items, we terminated the consensus procedure and communicated the
results to the CER SIG members. The Delphi flowchart is shown in Figure S2, while the last version of
cover letter and online questionnaire is available on the online Supplement 2.
The evaluation framework was built on the main domains and subdomains identified through the
Delphi process and it was used as an instrument to evaluate the completeness of the existing assessment
tools for cohort and case-control studies only or multiple NRS. The assessment of each domain and
subdomain and the distribution of domains in the reviewed tools are shown in Figures S3-S11.
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Table S1. Search strategy

Items
Critical appraisal
tool

N.
#1
#2
#3

Terms
"critical" [All Fields] AND "appraisal" [All Fields] AND "tools" [All Fields]
"critical" [All Fields] AND "appraisal" [All Fields]
("critical" [All Fields] AND "review" [All Fields]) OR "critical review" [All Fields]) AND form [All Fields]

#4

#14
#15
#16
#17
#18

("systematic review" [Publication Type] OR "systematic reviews as topic" [MeSH Terms] OR "systematic review"[All
Fields]) AND form [All Fields]
appraisal [All Fields] AND ("research design" [MeSH Terms] OR ("research" [All Fields] AND "design" [All Fields]) OR
"research design" [All Fields] OR ("research" [All Fields] AND "methodology" [All Fields]) OR "research methodology"[All
Fields])
("research design" [MeSH Terms] OR ("research" [All Fields] AND "design" [All Fields]) OR "research design" [All Fields])
AND ("review" [Publication Type] OR "review literature as topic" [MeSH Terms] OR "review"[All Fields])
"study" [All Fields] AND "reporting" [All Fields] AND "tool" [All Fields]
"study" [All Fields] AND "reporting" [All Fields]
"reporting" [All Fields] AND "form" [All Fields] AND ("Studies"[Journal] OR "studies"[All Fields])
"reporting" [All Fields] AND ("Studies"[Journal] OR "studies"[All Fields])
"checklist" [MeSH Major Topic] OR "scale*" [Title/Abstract]
"surveys and questionnaires"[MeSH Major Topic] OR "questionnaire*" [Title/Abstract]
("tool*" [All Fields] OR "instrument*" [All Fields] OR "checklist*" [All Fields] OR "questionnaire*" [All Fields]) AND
("quality" [All Fields] OR "method*" [All Fields] OR "bias" [All Fields])
"cohort studies"[MeSH Terms] OR cohort studies [Text Word] OR cohort stud* [All Fields]
"case-control studies" [MeSH Terms] OR case-control studies [Text Word] OR case control stud* [All Fields]
Non [All Fields] AND ("random allocation"[MeSH Terms] OR randomized [Text Word]) AND stud* [All Fields]
"systematic review" [Publication Type] OR "systematic reviews as topic"[MeSH Terms] OR "systematic review"[All Fields]
"humans"[MeSH Terms]

#19

"Review" [ptyp] OR "systematic" [sb]

#20
#21
#22
#23

(#1 OR #2 OR #3 OR #4 OR #5 OR #6) AND (#14 OR #15 OR #16) AND #18
(#7 OR #8 OR #9 OR #10) AND (#14 OR #15 OR #16) AND #18
(#11 OR #12 OR #13) AND (#14 OR #15 OR #16) AND #18
(#1 OR #2 OR #3 OR #4 OR #5 OR #6) AND (#14 OR #15 OR #16) AND #18 AND (#17 OR #19)

#5

#6
Study reporting
tool

Tool

Study design

Systematic review
Filters

Strings
1st search - tools*

2nd search systematic reviews
of tools*

#7
#8
#9
#10
#11
#12
#13

#24
(#7 OR #8 OR #9 OR #10) AND (#14 OR #15 OR #16) AND #18 AND (#17 OR #19)
#25
(#11 OR #12 OR #13) AND (#14 OR #15 OR #16) AND #18 AND (#17 OR #19)
*tools are defined as instruments (e.g., qualitative checklists, questionnaires, scoring scales, etc.) that investigate the overall quality of a study, identifying
potential biases – either used to critically appraise studies included in a systematic review, or to help in the peer-reviewing process of scientific publications
– (i.e., critical appraisal tools), or that support the reporting of research methods and findings (i.e. study reporting tools).
Note: the strings were built in Medline and then adapted to Embase (through Elsevier)
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Table S2. List of investigated websites of influential initiatives, programs or organizations.
Name of initiative, programs or institutions

Link to the website

STROBE (STrengthening the Reporting of OBservational studies in Epidemiology)
statement
Effective Health Care (EHC) Program of the Agency for Healthcare Research and
Quality (AHRQ)
The Ottawa Hospital – Research Institute
The Scottish Intercollegiate Guidelines Network (SIGN)
GRACE (Good ReseArch for Comparative Effectiveness) initiative
The Joanna Briggs Institute
TREND (Transparent Reporting of Evaluations with Nonrandomized Designs)
statement
CASP (Critical Appraisal Skills Programme)

https://strobe-statement.org/index.php?id=available-checklists
https://effectivehealthcare.ahrq.gov/research-methods
http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
https://www.sign.ac.uk/checklists-and-notes.html
https://www.graceprinciples.org/about-grace.html
http://joannabriggs.org/research/critical-appraisal-tools.html
https://www.cdc.gov/trendstatement/index.html
https://casp-uk.net/casp-tools-checklists/
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Figure S1. Flowchart of the selection of the tools

Records identified through database
searching
(n = 3,156)

Records identified from SRs,
investigated websites and other sources
(n = 223)

Records after duplicates removed
(n = 2,061)

Records screened
(n = 2,061)

Records excluded
(n = 1,954)

Full-text articles or tools
assessed for eligibility
(n = 107)

Full-text articles excluded,
(reasons listed in Table S3)
(n = 73)

Records retrieved for the
qualitative synthesis
(n = 34) *

Tools included in the
qualitative synthesis
(n = 44) *

*Ten retrieved articles/records included two different assessment tools for case-control and cohort studies. Thus, the overall
number of included tools raised up to 44.
The systematic reviews (SRs) were retrieved through a systematic search. Additional details about the SRs search are
available upon request.
NB. The reporting items in the flowchart follows the indications given by the PRISMA Statement at Moher D, Liberati A, Tetzlaff J,
Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA
Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097.
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Figure S2. Flowchart of the Delphi procedure

Definition of Delphi Goals
Identifying the key methodological challenges that can influence the overall
quality of a study
Expert Group Selection
Special Interest Group of the International Society for Pharmacoepidemiology
Comparative Effectiveness Research
Round I
Participants rated the key methodological challenges (or domains and
subdomains) assigning a score from 1 (not important) to 5 (extremely important).
Consensus was reached on many of the proposed domains and subdomains.
Two subdomains have been added and one removed according to the feedback
received by participants.
Round II
Participants rated the revised key methodological challenges assigning a score
from 1 (not important) to 5 (extremely important).
Consensus
Consensus equal or higher than 70% was reached for all domains and
subdomains
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Table S3. Excluded tools after full-text screening
Reference (73 article excluded)

Reason for
exclusion

Berkman ND, Lohr KN, Ansari M, et al. Chapter 15 Appendix A: A Tool for Evaluating the Risk
of Reporting Bias (in Chapter 15: Grading the Strength of a Body of Evidence When Assessing
Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare
Research and Quality: An Update). Methods Guide for Comparative Effectiveness Reviews
(Prepared by the RTI-UNC Evidence-based Practice Center under Contract No. 290-200710056-I). AHRQ Publication No. 13(14)-EHC130-EF. Rockville, MD: Agency for Healthcare
Research and Quality, 2013
Balshem H, Stevens A, Ansari M, et al. Finding grey literature evidence and assessing for
outcome and analysis reporting biases when comparing medical interventions: AHRQ and the
Effective Health Care Program. (Prepared by the Oregon Health and Science University and the
University of Ottawa Evidence-based Practice Centers under Contract Nos. 290-2007-10057-I
and 290-2007-10059-I.) AHRQ Publication No. 13(14)-EHC096-EF. Rockville, MD: Agency for
Healthcare Research and Quality, 2013

Assessment of
systematic reviews

Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of
evidence and strength of recommendations. BMJ 2008; 336:924–6.

Assessment to
provide strength of
recommendations
Assessment of
studies of
prognostic factors
Assessment of
RCTs

Hayden JA van der Windt DA, Cartwright JL, et al. Assessing bias in studies of prognostic
factors. Ann Intern Med 2013; 158:280–6.
Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In:
Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version
5.1.0. London: The Cochrane Collaboration, 2011.
Higgins JPT, Savović J, Page MJ, et al. Revised Cochrane risk of bias tool for randomized trials
(RoB 2.0), Version 20. 2016 Available at: https://sites. google.com/site/riskofbiastool/ (accessed
19 Sep 2019)
Hooijmans CR, Rovers MM, de Vries RB, et al. SYRCLE's risk of bias tool for animal studies.
BMC Med Res Methodol 2014; 14:43
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non‐
randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg.
2003;73(9): 712‐716.
Centre for reviews and dissemination. Systematic Reviews: CRD's Guidance for Undertaking
Reviews in Healthcare. 3rd ed. UK: University of York; 2009.
Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non‐randomised intervention studies. Health
Technol. Assess (Winchester, England. 2003;7(27): iii‐x):1‐173.
NICE. Guide to the methods of technology appraisal 2013. Updated 2016.
University of Wales College of Medicine. Critical Appraisal Forms. University of Wales, 2004.
Loney PL, Chambers LW, Bennett KJ, Roberts JG, Stratford PW. Critical appraisal of the health
research literature: prevalence or incidence of a health problem. Chronic Dis Canada
2000;19:170–77.
Cameron I, Crotty M, Currie C et al. Geriatric rehabilitation following fractures in older people:
a systematic review. Health Technol Assess 2000;4: i–111.
Carneiro AV. Critical appraisal of prognostic evidence: practical rules. Rev Port Cardiol 2002;
21:891–900.
Centre for Evidence-Based Mental Health, University of Oxford. Critical Appraisal Forms. 2004.
Available at: http://www.cebmh.com/ (accessed 19 Sep 2019)

Assessment of
reporting bias,
guidance

Assessment of
RCTs
Assessment of
animal studies
Assessment of
NRS of surgical
interventions
No assessment tool,
guidance for
reviews
No assessment tool,
original research
No assessment tool,
guidance for HTA
N/A
No structured
assessment tool
No assessment tool
Assessment tool of
prognostic studies
Assessment tool
tailored to a
particular
disease/topic
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Esdaile JM, Horwitz RI. Observational studies of cause-effect relationships: an analysis of
methodologic problems as illustrated by the conflicting data for the role of oral contraceptives in
the etiology of rheumatoid arthritis. J Chronic Dis 1986; 39:841–52.
Khan KS, Riet GT, Popay J, Nixon J, Kleijnen J. Undertaking systematic reviews of research
effectiveness. CRD’s guidance for those carrying out or commissioning reviews. CRD Report
number 4 (2nd edn). 2001. The University of York Centre for Reviews and Dissemination.
How to read clinical journals: IV. To determine etiology or causation. Can Med Assoc J.
1981;124(8):985‐990.
Mulrow CD, Lichtenstein MJ. Blood glucose and diabetic retinopathy: a critical appraisal of new
evidence. J Gen Intern Med 1986; 1:73–77.

Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of QUADAS: a
tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews.
BMC Med Res Methodol 2003; 3:25.
Campbell H, Rudan I. Interpretation of genetic association studies incomplex disease.
Pharmacogenomics J 2002; 2:349–60.

Solomon DH, Bates DW, Panush RS, Katz JN. Costs, outcomes, and patient satisfaction by
provider type for patients with rheumatic and musculoskeletal conditions: a critical review of the
literature and proposed methodologic standards. Ann Intern Med 1997; 127:52–6
The STARD Group. The STARD Initiative—Towards Complete and Accurate Reporting of
Studies on Diagnostic Accuracy. http://www.consort-statement.org/stardstatement.htm, 2001.
Critical appraisal: Guidelines for the critical appraisal of a paper. Surgical-Tutor.org.uk, 2004.
Zola P, Volpe T, Castelli G et al. Is the published literature a reliable guide for deciding between
alternative treatments for patients with early cervical cancer? Int J Radiat Oncol Biol Phys
1989;16:785–97.
Bollini P, Garcia Rodriguez LA, Gutthann SP, Walker AM. The impact of research quality and
study design on epidemiologic estimates of the effect of nonsteroidal anti-inflammatory drugs on
upper gastrointestinal tract disease. Arch Intern Med 1992; 152:1289–95.
Ciliska D, Hayward S, Thomas H et al. A systematic overview of the effectiveness of home
visiting as a delivery strategy for public health nursing interventions. Can J Public Health
1996;87:193–98.
Cowley DE. Prostheses for primary total hip replacement. A critical appraisal of the literature. Int
J Technol Assess Health Care 1995;11:770–78.
Spitzer WO, Lawrence V, Dales R et al. Links between passive smoking and disease: a bestevidence synthesis. A report of the Working Group on Passive Smoking. Clin Invest Med
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Steinberg EP, Eknoyan G, Levin NW et al. Methods used to evaluate the quality of evidence
underlying the National Kidney Foundation- Dialysis Outcomes Quality Initiative Clinical
Practice Guidelines: description, findings, and implications. Am J Kidney Dis 2000; 36:1–11.
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Figure S3. Assessment tools that included or not at least one question/item to address subdomains of methods for selecting study
participants (Domain 1), stratified by study design.
Domain 1 - Methods for selecting participants (SELECTION BIAS)
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(#) tool developed to assess NRS on the comparative safety and effectiveness of medications.
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Figure S4. Assessment tools that included or not at least one question/item to address subdomains for measurement of exposure,
outcomes, covariate variables and follow-up (Domain 2), stratified by study design.
Domain 2 - Measurement of exposure, outcomes, covariate variables and
follow-up.
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Legend: ✓ = at least one item/question addressing the subdomain; × = not items/questions addressing the subdomain.
(#) tool developed to assess NRS on the comparative safety and effectiveness of medications.
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Figure S5. Assessment tools that included or not at least one question/item to address subdomains to detect design-specific sources of
biases (Domain 3), stratified by study design.
Domain 3 - Design-specific sources of bias
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Legend: ✓ = at least one item/question addressing the subdomain; × = not items/questions addressing the subdomain.
(#) tool developed to assess NRS on the comparative safety and effectiveness of medications.
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Figure S6. Assessment tools that included or not at least one question/item to address confounding (Domain 4), stratified by study
design.
Domain 4 - Confounding
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Legend: ✓ = at least one item/question addressing the subdomain; × = not items/questions addressing the subdomain.
(#) tool developed to assess NRS on the comparative safety and effectiveness of medications.
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Figure S7. Assessment tools that included or not at least one question/item to address lack of appropriateness of statistical analyses
(Domain 5), methods for assessing statistical uncertainty in the findings (Domain 6), methods for assessing internal validity (Domain
7), methods for assessing external validity (Domain 8), stratified by study design.
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Legend: ✓ = at least one item/question addressing the subdomain; × = not items/questions addressing the subdomain.
(#) tool developed to assess NRS on the comparative safety and effectiveness of medications.
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Supplement file 2
Survey to the experts of the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness
Research (CER) - Special Interest Group:
FRAMEWORK TO EVALUATE ASSESSMENT TOOLS
Dear Member,
As an expert contributor to the International Society for Pharmacoepidemiology (ISPE) Comparative Effectiveness
Research (CER) Special Interest Group, we would like to invite you to take part in a short survey aimed at identifying
key quality domains that:
(i) should be considered when assessing the overall quality of a nonrandomized study (NRS) in
pharmacoepidemiology, and;
(ii) are not covered by existing appraisal tools for assessing the quality of NRSs.
Your answers will be used to inform the research project on an evaluation of existing tools to assess the
methodological quality of pharmacoepidemiological NRSs - specifically cohort and case-control studies.
The survey will take approximately 5 minutes to complete and consists of two sections:
A. Demographic and professional information
B. Evaluation of key quality domains
In SECTION A, you will be asked to provide your demographic and professional information.
SECTION B lists key domains in assessing the overall quality of NRSs in pharmacoepidemiology.
Each key domain is presented as an item that can be part of a tool for evaluating the methodological quality of
pharmacoepidemiological NRSs (cohort and case control designs). You are asked to evaluate the importance of each
item, rating it from 1 (not important) to 5 (extremely important). At the end of section B, you will have the
opportunity to report additional items that were not presented in the survey, are key for evaluating the
methodological quality of pharmacoepidemiological NRSs and are not included in current appraisal tools.
Your answers will be kept strictly confidential and will be used only for the purposes of this research project. The
results will be reported in aggregate form only and will be part of a publication in a peer-reviewed journal.
Should you have any questions on the survey or the project, please contact Elvira D'Andrea at
edandrea@bwh.harvard.edu or Lydia Vinals at lydia.vinals@evidera.com.
We thank you for your collaboration.
Grammati Sarri (grammati.sarri@evidera.com)
Thomas Debray (t.debray@umcutrecht.nl)
Research Project coordinators.
Elisabetta Patorno (epatorno@bwh.harvard.edu)
Chair, ISPE CER Special Interest Group.
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Section A – Demographic and professional info

Institution or Organization:
– Academia
– Industry
– Governmental Agencies
– Other (specify) _____________
Professional position

___________________________________________________________

Country

___________________________________________________________

Section B - Evaluation of key quality domains

Please rate the following items from 1 (not important) to 5 (extremely important). Your judgment should be based
on the importance that the key domains described by each item should have in tools assessing the overall
methodological quality of a pharmacoepidemiologic NRS.
How important is it for a tool to assess:
1. Methods for selecting participants (selection bias)
Not important

1

2

3

4

5

Extremely important

3

4

5

Extremely important

Specifically:
1.1 Sampling strategies to correct selection bias
Not important

1

2

2.1 Inclusion and exclusion criteria of target population clearly defined
Not important

1

2

3

4

5

Extremely important

2

3

4

5

Extremely important

2

3

4

5

Extremely important

2.2 Depletion of susceptibles
Not important

1

2.3 Methods of selecting participants*
Not important

1

2
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2.4 Other key source of selection bias not included above ____________________

*question added to the questionnaire of the second round of the Delphi survey based on the answers
provided on the first round.

2. Definition and measurement of exposure, outcomes, covariate variables and follow-up.
Not important

1

2

3

4

5

Extremely important

3

4

5

Extremely important

3

4

5

Extremely important

3

4

5

Extremely important

Specifically:
2.1 Definition and measurement of exposure
Not important

1

2

2.2 Definition and measurement of outcomes
Not important

1

2

2.3 Definition and measurement of covariate variables
Not important

1

2

2.4 Definition and measurement of follow-up
Not important

1

2

3

4

5

Extremely important

1

2

3

4

5

Extremely important

2

3

4

5

Extremely important

2

3

4

5

Extremely important

5

Extremely important

3. Design-specific sources of bias:
Not important

Specifically:
3.1 lack of use of new user design:
Not important

1

3.2 lack of use of active comparator:
Not important

1

3.3 Time-related biases (immortal time bias or window-time bias):
Not important

1

2

3

4

3

D'Andrea E, et al. BMJ Open 2021; 11:e043961. doi: 10.1136/bmjopen-2020-043961

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

Supplemental material

BMJ Open

3.4 Detection or surveillance bias:
Not important

1

2

3

4

5

Extremely important

1

2

3

4

5

Extremely important

3.5 Loss to follow-up bias:
Not important

3.6 Non-contemporaneous comparator bias:
Not important

1

2

3

4

5

Extremely important

1

2

3

4

5

Extremely important

1

2

3

4

5

Extremely important

3.7 Reverse causation:
Not important
3.8 Recall bias#:
Not important

3.10 Other critical design-specific sources of bias not mentioned above _________

#

question removed to the questionnaire of the second round of the Delphi survey based on the answers
provided on the first round.

4. Confounding:
Not important

1

2

3

4

5

Extremely important

4

5

Extremely important

4

5

Extremely important

Specifically:
4.1 Study design used to minimize the confounding:
Not important

1

2

3

4.2 Confounders measured and included in the analyses
Not important

1

2

3

4.3 Potential unmeasured confounding (addressed in the analysis through proxy analysis, IV analysis, etc.)
Not important

1

2

3

4

5

Extremely important

4.4 Other critical elements for confounding not mentioned above _________

4
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5. Lack of appropriateness of statistical analyses (with specific mention of adjustment for causal intermediaries,
and/or incorrect outcome model specification)
Not important

1

2

3

4

5

Extremely important

6. Methods for assessing statistical uncertainty in the findings (e.g., confidence intervals reported for each analysis)
Not important

1

2

3

4

5

Extremely important

7. Methods for assessing internal validity (e.g. sensitivity analysis addressing potential confounding, measurement
errors or other biases)
Not important

1

2

3

4

5

Extremely important

8. Methods for assessing external validity (e.g. post-hoc subgroup analysis, comparison with other populations etc.)
Not important

1

2

3

4

5

Extremely important

9. Any other key considerations not listed above ________________________________________
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GLOSSARY
SELECTION BIAS defined as a bias due to a sample selection that does not accurately reflect the target population.
DEPLETION OF SUSCEPTIBLES is defined as a phenomenon where the initiation of exposure to a drug is associated
with an early increase in the incidence rate of an acute event, followed by a decrease in this incidence rate with
longer duration of exposure.
NEW USER DESIGN, defined as a study design that starts following patients at the time they initiate a new drug (also
known as incident user design).
ACTIVE COMPARATOR DESIGN, defined as a study design that compares the effect of the drug of interest with
another drug used in clinical practice instead of non-use.
IMMORTAL TIME BIAS, defined as a bias that derives from including a period of follow-up during which, by design,
outcomes cannot occur.
WINDOW-TIME BIAS, in the context of a case-control study nested in a cohort, defined as a bias that derives from
the use of time-windows of different lengths between cases and controls to define time-dependent exposures.
DETECTION OR SURVEILLANCE BIAS, defined as a bias that derives from systematic differences in outcomes
assessment among groups being compared.
NON-CONTEMPORANEOUS COMPARATOR BIAS, defined as a bias generated by differences in the timing of selection
of comparator group(s) within a study influence exposures and outcomes resulting in biased estimates.
REVERSE CAUSATION (or reverse causality), defined as a direction of cause-and-effect contrary to a common
presumption, or a two-way causal relationship between exposure and outcome.
RECALL BIAS, defined as a bias that occurs when participants do not remember previous events or experiences
accurately or omit details (not for claims-based studies).
LOSS TO FOLLOW-UP BIAS, defined as a bias that occurs when there is difference in retention during the follow-up
period after enrollment that are related to exposure status and outcome. It can be considered as part of selection
bias.
CONFOUNDING, defined as a mixing of effects that arises when patients with different baseline risks are compared –
the resulting effect measure is a mix of drug effects and risk factor effects.
ADJUSTMENT FOR CAUSAL INTERMEDIARIES, defined as adjustment for an intermediate variable (or a descending
proxy for an intermediate variable) on a causal path from exposure to outcome.
INCORRECT OUTCOME MODEL SPECIFICATION, for omission of a relevant variable, inclusion of an unnecessary
variable, adopting the wrong functional form, incorrect specification of the error term, uncertainty about what the
true model is, reciprocal causation, etc.

6
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